{"id":1735,"date":"2023-06-25T17:40:08","date_gmt":"2023-06-25T17:40:08","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/ciprofibrate\/"},"modified":"2023-06-25T19:42:09","modified_gmt":"2023-06-25T19:42:09","slug":"ciprofibrate","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/ciprofibrate\/","title":{"rendered":"Ciprofibrate"},"content":{"rendered":"

<\/p>\n

Ciprofibrate<\/h1>\n

CLINICAL USE<\/h3>\n

Hyperlipidaemia<\/p>\n

DOSE IN NORMAL RENAL FUNCTION<\/h3>\n

100 mg daily<\/p>\n

PHARMACOKINETICS<\/h3>\n
  • Molecular weight                           :289.2<\/li>\n
  • %Protein binding                           :95\u201399<\/li>\n
  • %Excreted unchanged in urine     : 20\u201325<\/li>\n
  • Volume of distribution (L\/kg)       :12 litres<\/li>\n
  • half-life \u2013 normal\/ESRD (hrs)      :38\u201386\/171.9
    \n

    DOSE IN RENAL IMPAIRMENT<\/h3>\n

    GFR (mL\/MIN)<\/h4>\n<\/li>\n
  • 20 to 50     : Dose as in normal renal function<\/li>\n
  • 10 to 20     : 100 mg every 48 hours<\/li>\n
  • <10           : Avoid. See \u2018Other Information\u2019
    \n

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES<\/h3>\n<\/li>\n
  • CAPD                :Not dialysed. Avoid<\/li>\n
  • HD                     :Not dialysed. Avoid<\/li>\n
  • HDF\/high flux   :Unknown dialysability. Avoid<\/li>\n
  • CAV\/VVHD      :Unknown dialysability. Dose as in GFR 10 to 20 mL\/min
    \n

    IMPORTANT DRUG INTERACTIONS<\/h3>\n

    Potentially hazardous interactions with other drugsAntibacterials: increased risk of myopathy with daptomycin \u2013 try to avoid concomitant useAnticoagulants: enhances effect of coumarins and phenindione. Dose of anticoagulant should be reduced by up to 50% and readjusted by monitoring INRAntidiabetics: may improve glucose tolerance and have an additive effect with insulin or sulphonylureasLipid-regulating drugs: increased risk of myopathy in combination with statins (do not exceed 10 mg of simvastatin1) and ezetimibe \u2013 avoid concomitant use with ezetimibe<\/p>\n

    ADMINISTRATION<\/h3>\n

    Reconstition<\/h4>\n

    \u2013<\/p>\n

    Route<\/h4>\n

    Oral<\/p>\n

    Rate of Administration<\/h4>\n

    \u2013<\/p>\n

    Comments<\/h4>\n

    \u2013<\/p>\n

    OTHER INFORMATION<\/h4>\n

    Increased risk of rhabdomyolysis in doses of 200 mg or greaterApproximately 30\u201375% of a single dose administered to volunteers was excreted in the urine in 72 hours, either as unchanged ciprofibrate (20\u201325% of the total excreted) or as a conjugate. Subjects with moderate renal impairment excreted on average 7% of a single dose as unchanged ciprofibrate over 96 hours, compared with 6.9% in normal subjects. In subjects with severe insufficiency this was reduced to 4.7%<\/li>\n","protected":false},"excerpt":{"rendered":"

    Ciprofibrate CLINICAL USE Hyperlipidaemia DOSE IN NORMAL RENAL FUNCTION 100<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-1735","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1735","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=1735"}],"version-history":[{"count":1,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1735\/revisions"}],"predecessor-version":[{"id":2848,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1735\/revisions\/2848"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=1735"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=1735"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=1735"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}